dc.contributor.author | Martin-Blazquez, Ariadna | |
dc.contributor.author | Martin-Lorenzo, Marta | |
dc.contributor.author | Santiago-Hernandez, Aranzazu | |
dc.contributor.author | Heredero, Angeles | |
dc.contributor.author | Donado, Alicia | |
dc.contributor.author | Lopez, Juan A | |
dc.contributor.author | Anfaiha-Sanchez, Miriam | |
dc.contributor.author | Ruiz-Jimenez, Rocio | |
dc.contributor.author | Esteban, Vanesa | |
dc.contributor.author | Vazquez, Jesus | |
dc.contributor.author | Aldamiz-Echevarria, Gonzalo | |
dc.contributor.author | Alvarez-Llamas, Gloria | |
dc.date.accessioned | 2024-05-17T10:02:17Z | |
dc.date.available | 2024-05-17T10:02:17Z | |
dc.date.issued | 2024-04-09 | |
dc.identifier.citation | J Proteome Res. 2024 Apr 9. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/19444 | |
dc.description.abstract | Thoracic aortic aneurysm (TAA) is mainly sporadic and with higher incidence in the presence of a bicuspid aortic valve (BAV) for unknown reasons. The lack of drug therapy to delay TAA progression lies in the limited knowledge of pathophysiology. We aimed to identify the molecular hallmarks that differentiate the aortic dilatation associated with BAV and tricuspid aortic valve (TAV). Aortic vascular smooth muscle cells (VSMCs) isolated from sporadic TAA patients with BAV or TAV were analyzed by mass spectrometry. DNA oxidative damage assay and cell cycle profiling were performed in three independent cohorts supporting proteomics data. The alteration of secreted proteins was confirmed in plasma. Stress phenotype, oxidative stress, and enhanced DNA damage response (increased S-phase arrest and apoptosis) were found in BAV-TAA patients. The increased levels of plasma C1QTNF5, LAMA2, THSB3, and FAP confirm the enhanced stress in BAV-TAA. Plasma FAP and BGN point to an increased inflammatory condition in TAV. The arterial wall of BAV patients shows a limited capacity to counteract drivers of sporadic TAA. The molecular pathways identified support the need of differential molecular diagnosis and therapeutic approaches for BAV and TAV patients, showing specific markers in plasma which may serve to monitor therapy efficacy. | es_ES |
dc.description.sponsorship | This study was supported by the Instituto de Salud Carlos III
with cofunding from the ERDF (PI20/01103, CP22/00100,
FI21/00128, IF08/3667-1, PI21/00158, PRB3[IPT17/0019-
ISCIII-SGEFI/ERDF], RD16/0009, RD21/0005/0001), the
Spanish Ministry of Science, Innovation and Universities
(PGC2018-097019-B-I00 and PID2021-122348NB-I00), Getinge Group Spain SL, CAM (PEJ-2020-AI/BMD-17899,
PEJD-2019-PRE/BMD-16992, 2018-T2/BMD-11561, PIPF2022/SAL-GL-25760), Fundacioń SENEFRO/SEN, Fundacioń Mutua Madrileña and Fundacioń Conchita Rabago ́ de
Jimenez ́ Dí
az, and “la Caixa” Banking Foundation (project
codes HR17-00247 and HR22-00253). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the
Ministerio de Ciencia e Innovacioń (MCIN), and the Pro
CNIC Foundation) and is a Severo Ochoa Center of
Excellence (grant CEX2020-001041-S funded by MICIN/
AEI/10.13039/501100011033). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | American Chemical Society (ACS) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.title | Analysis of Vascular Smooth Muscle Cells from Thoracic Aortic Aneurysms Reveals DNA Damage and Cell Cycle Arrest as Hallmarks in Bicuspid Aortic Valve Patients. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 38594816 | es_ES |
dc.identifier.doi | 10.1021/acs.jproteome.3c00649 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | es_ES |
dc.contributor.funder | Ministerio de Ciencia, Innovación y Universidades (España) | es_ES |
dc.contributor.funder | Comunidad de Madrid (España) | es_ES |
dc.contributor.funder | Fundación Mutua Madrileña | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | es_ES |
dc.contributor.funder | Fundación Conchita Rábago de Jiménez Díaz | es_ES |
dc.contributor.funder | Fundación La Caixa | es_ES |
dc.contributor.funder | Fundación ProCNIC | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1535-3907 | es_ES |
dc.relation.publisherversion | 10.1021/acs.jproteome.3c00649 | es_ES |
dc.identifier.journal | Journal of proteome research | es_ES |
dc.repisalud.orgCNIC | CNIC::Grupos de investigación::Proteómica cardiovascular | es_ES |
dc.repisalud.institucion | CNIC | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PI20/01103 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/CP22/00100 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/FI21/00128 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/IF08/3667-1 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PI21/00158 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RD16/0009 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/RD21/0005/0001 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PGC2018-097019-B-I00 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PID2021-122348NB-I00 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PEJ-2020-AI/BMD-17899 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PEJD-2019-PRE/BMD-16992 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/2018-T2/BMD-11561 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/PIPF2022/SAL-GL-25760 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/HR17-00247 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/HR22-00253 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/MICIN/AEI/10.13039/501100011033/CEX2020-001041-S | es_ES |